

1 **Complementary non-sputum diagnostic testing using oral swabs and urine LAM** 2 **testing for TB in people with HIV**

3
4 Running title: Oral swabs & urine LAM for TB diagnosis

5
6 Adrienne E. Shapiro^{1,2}, Alaina M. Olson³, Lara Kidoguchi¹, Xin Niu⁴, Zinhle Ngcobo⁵, Zanele P.
7 Magcaba⁵, Mduduzi W. Ngwane⁵, Grant R. Whitman³, Kris M. Weigel³, Rachel C. Wood³, Doug
8 P.K. Wilson^{5,6}, Paul K. Drain^{1,2}, Gerard A. Cangelosi^{1,3,4*}

9
10 ¹Department of Global Health, University of Washington, Seattle, WA, USA; ²Department of
11 Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA,
12 USA; ³Department of Environmental and Occupational Health Sciences, University of
13 Washington, Seattle, WA, USA; ⁴Department of Epidemiology, University of Washington, Seattle,
14 WA, USA; ⁵Umkhuseleli Research and Innovation Management, Pietermaritzburg, South Africa;
15 ⁶University of KwaZulu-Natal, Pietermaritzburg, South Africa

16
17 *Corresponding author: Gerard Cangelosi, Dept. of Environmental and Occupational Health
18 Sciences, Box 351618, University of Washington, Seattle, WA 98195. Email: gcang@uw.edu

19
20 Key words: tuberculosis, oral swabs, diagnostic, urine, non-sputum, lipoarabinomannan (LAM),
21 OSA, tongue swabs.

22

23 **Abstract**

24 Testing for mycobacterial lipoarabinomannan (LAM) in urine is a practical but insensitive
25 alternative to sputum testing to diagnose tuberculosis (TB) in people with HIV (PWH). We
26 evaluated urine LAM testing conducted in parallel with tests for *Mycobacterium tuberculosis*
27 DNA in oral swabs. In a cohort of 131 South Africans (92% with HIV), combined urine LAM and
28 oral swab testing was significantly more sensitive than either sample tested alone (57% vs. 35%
29 and 39%, respectively), and 97% specific, compared to reference sputum testing (TB culture
30 and Xpert Ultra). Complementary non-sputum sample testing increased sensitivity of TB
31 diagnosis, without sacrificing specificity.

32

33

34

35 **Background**

36 Tuberculosis disease (TB), caused by *Mycobacterium tuberculosis* (MTB), remains a
37 major cause of illness and death in PWH [1]. The standard sample for TB diagnosis is sputum,
38 which can be difficult for PWH to produce and insensitive in some patients. The availability of
39 noninvasive alternatives to sputum testing would substantially improve TB care for PWH [2, 3].

40 Immunoassays for mycobacterial lipoarabinomannan (LAM) in urine are potential
41 alternatives to sputum testing. However, the single WHO-approved urine LAM test (by
42 Alere/Abbott) lacks sensitivity. Although next-generation urine LAM tests are in development or
43 evaluation, even best-performing tests of the LAM analyte alone may not be optimally sensitive
44 to detect TB disease in PWH [4, 5].

45 In search of an alternative non-sputum sample type, we and others have shown that
46 MTB DNA can be detected by oral swab analysis (OSA) [6-14]. In OSA, the dorsum of the
47 tongue is brushed with a sterile swab, and the collected material is tested for MTB DNA. This
48 non-invasive, non-sputum sample collection approach can be applied to any patient, in any
49 setting, including tertiary hospital, outpatient clinic, remote health point, or home and community
50 settings.

51 Despite their promise, to date neither OSA nor urine LAM testing has proven to be
52 sensitive enough to detect all TB in PWH. We hypothesize that sensitivity is limited for different
53 reasons in the two methods. For example, pulmonary disease may be required to deposit
54 enough MTB in the mouth for detection by OSA, whereas a very high total mycobacterial burden,
55 including extrapulmonary disease, may be required for transrenal passage of MTB glycolipids
56 into urine. Therefore, a parallel approach using both methods may detect more TB cases in
57 PWH than either method alone. The current study was conducted to assess the
58 complementarity of the two methods.

59

60 **Methods**

61 Participant enrollment: South African adults (age ≥ 16 years) with HIV (regardless of
62 symptoms), or adults with TB symptoms or a positive sputum Xpert Ultra TB test, were
63 consecutively enrolled into the prospective PROVE-TB cohort at Edendale Hospital and
64 affiliated clinics in Pietermaritzburg, South Africa between October 2019 and February 2021.
65 Persons who had received TB treatment for more than 24 hours were excluded. Clinical,
66 laboratory, and demographic data were collected from participants and clinical charts. Sputum,
67 urine, tongue swab, and blood samples were collected at bedside and transported to the on-site
68 laboratory for processing and analysis. Study data were collected and managed using REDCap
69 electronic data capture tools hosted at the Institute of Translational Health Sciences. All
70 participants provided written informed consent. This study was approved by the ethical
71 committees of the University of KwaZulu-Natal (BREC #BE475/18) and the University of
72 Washington.

73 Sample collection and analysis. Expecterated sputum samples were tested with Cepheid
74 GeneXpert MTB/RIF Ultra (Xpert Ultra) and mycobacterial culture (National Health Laboratory
75 System, South Africa). A TB case was defined as a participant with either a positive sputum
76 Xpert Ultra or a positive sputum TB culture result (reference testing). Spontaneously passed
77 urine samples were tested for the presence of LAM using the Alere DETERMINE LAM Ag
78 lateral-flow assay. A result of 1+ or higher according to the manufacturer's visual read-out card
79 was considered positive. Two tongue dorsum swabs (Copan FLOQSwabs) were collected into
80 separate tubes as described previously [7, 8]. Swabs in 0.5 mL TE buffer were stored frozen at -
81 80 °C and transported to the Cangelosi Lab for blinded analysis. Thawed samples were
82 manually processed (Qiagen), concentrated by ethanol precipitation, and tested by IS6110-
83 targeted qPCR. Swab analysis methods were as described previously [7, 8] with the following

84 modifications. Post-boil samples were eluted from the swab head then split, 250 μ L reserve and
85 250 μ L for immediate processing by volume-scaled-lysis (300 μ L each of Qiagen Buffer AL and
86 100% ethanol). The qPCR protocol used New England BioLabs® Inc Luna® Universal Probe
87 qPCR Master Mix, and the ethanol-precipitated samples were rehydrated in 5 μ L TE buffer prior
88 to master mix addition. Cq values were recorded and results were calculated using two Cq
89 thresholds (38 as described previously [7, 8], and a more stringent value of 32).

90 In addition, a subset of reserved or duplicate oral swab samples (N=18) were tested
91 using by either of two methods. In one method, previously boiled, reserved (200 μ L) half
92 samples were thawed and received 2.2 mL TE buffer. The samples were shaken on a lab
93 vortexer (GENIE® SI-0236 Vortex-Genie 2 Mixer, 120V) on setting 10 for 10-15 seconds, then
94 allowed to sit at ambient temperature for 5 minutes and then shaken for an additional 10-15
95 seconds, before allowing them sit for additional 10 minutes at ambient temperature. The entire
96 recoverable sample volume was transferred into the sample reservoir of the Xpert Ultra
97 cartridge for analysis. Samples were recorded as positive for MTB if GeneXpert software
98 returned any positive result. Some samples were run by an alternative method that did not use
99 heat. These 0.5-mL samples were thawed at ambient temperature for 30 min, then
100 supplemented with 0.3 mL TE and 1.6 mL of Cepheid Sample Reagent (SR). The samples were
101 vortexed for 10-15 seconds, and incubated for 5 minutes before vortexing for an additional 10-
102 15 seconds. The samples were further incubated for additional 10 minutes before the entire
103 sample volume was transferred to the cartridges.

104 Sensitivities and specificities of index methods (swabs, urine LAM, and parallel testing)
105 were calculated relative to the reference method (positive sputum Xpert Ultra or positive sputum
106 culture).

107

108

109 **Results**

110 We enrolled 131 participants (45% female, median age 36 years) who provided all
111 sample types for index and reference testing. 120 (92%) participants had HIV. 64 (49%) were
112 TB cases by reference testing (**Figure 1**).

113 Relative to the sputum reference standard, OSA using manual qPCR conducted on a
114 single swab, with a Cq cutoff of 38, was significantly more sensitive than urine LAM
115 (respectively, 42/64 [67%] vs. 22/63 [35%]). However, OSA was less specific than urine LAM
116 (respectively, 52/67 [78%] vs. 67/67 [100%]). When a more stringent Cq cutoff of 32 was
117 applied to define a positive OSA result, OSA and urine LAM performed similarly (respectively,
118 25/64 [39%] vs. 22/63 [35%] sensitive, and 65/67 [97%] vs. 67/67 [100%] specific) (**Table 1**).

119 When evaluating parallel (combination) non-sputum testing, a positive index test was
120 defined as being either urine LAM-positive or OSA-positive. With parallel testing, sensitivity
121 improved to 36/63 [57%], significantly better than urine LAM alone ($p=0.006$) or OSA alone
122 ($p=0.021$). Of the 36 participants who were true positive by non-sputum methods, 11 were
123 positive by both methods while 25 were positive by only one or the other (14 by OSA and 11 by
124 urine LAM; **Figure 1**). Specificity of the combined method remained high at 65/67 (97%).

125 The manual qPCR method used in Table 1 performed well in past OSA studies [7, 8, 14]
126 but is impractical for routine diagnostic use. Therefore, as a secondary analysis we used the
127 semi-automated Cepheid GeneXpert MTB/RIF Ultra platform to test a subset of 18 frozen swab
128 samples from the current study (11 true positives with strong qPCR signals by OSA, 5 true
129 negatives by OSA, and the 2 false positives by OSA). Xpert Ultra detected 10 of 11 true
130 positives by OSA (the 11th sample had an invalid Xpert Ultra result). It correctly excluded all 5
131 true negatives by OSA. It also correctly excluded the 2 false positives by OSA (**Table S1**).

132

133 Discussion

134 Many PWH struggle to produce sputum (sputum-scarce) and/or have low MTB cell
135 counts in sputum (paucibacillary) [2, 3]. This study tested the hypothesis that parallel testing of
136 two different non-sputum samples can deliver complementary, not redundant diagnostic
137 information, and thereby serve as an alternative to sputum testing for at least some patients.

138 Recent years have seen advancements in urine LAM testing for sputum-scarce or
139 paucibacillary patients. LAM is an MTB cell wall glycolipid that can pass transrenally into urine.
140 In some patients, most notably PWH with low CD4 counts, LAM is found in the urine in sufficient
141 quantities to enable rapid detection by using lateral flow tests such as the Alere Determine™ TB
142 LAM Ag. However, the sensitivity of urine LAM tests remains suboptimal [4, 5].

143 We hypothesized that OSA can improve TB diagnosis in paucibacillary and sputum-
144 scarce patients when used in combination with urine LAM testing. The physiological bases for
145 urine LAM testing (transrenal passage of a mycobacterial glycolipid) and OSA (deposition of
146 MTB cells and/or DNA on the tongue dorsum during cough, exhalation, or spontaneous sputum
147 production) are likely to differ from each other. Urine LAM may work best in cases that are at
148 least partially extrapulmonary, while OSA may be best in pulmonary TB. The strengths and
149 limitations of the two methods may therefore complement each other.

150 The results were consistent with this hypothesis. When the more stringent Cq cutoff of
151 32 was applied, a diagnostic criterion of positivity in either urine LAM or OSA was significantly
152 more sensitive than either method alone. Specificity was acceptable at 97% and was the
153 minimum of the individual test specificities, but not lower in combination.

154 This study focused on the biological question of complementarity. Limitations associated
155 with implementation were only partially addressed. While swab sample collection has minimal
156 resource requirements, the manual qPCR method for OSA requires laboratory facilities,
157 specialized equipment and skilled technical operators, so is not practical for routine clinical

158 laboratory use in its current form. However, analysis of a subset of 18 samples with the near
159 point-of-care Xpert Ultra platform suggested that similar results can be obtained with automated
160 tests (with the caveat that the true-positive samples within the subset were strongly positive by
161 manual qPCR). Therefore, this strategy can in theory be applied in any setting with access to
162 both Alere Determine™ TB LAM AG and Xpert Ultra. Other automated amplification platforms
163 intended for near-point-of-care or point-of-care use are also in development and have the
164 potential to be configured for TB OSA.

165 Another implementation concern is the requirement for two laboratory tests per patient.
166 In context, the same limitation often applies to the current sputum-dependent strategies
167 (paucibacillary and sputum-scarce patients often require multiple sampling and testing attempts
168 to confirm TB). Urine and tongue swabs are easier and safer to collect than sputum samples in
169 most settings. To conserve resources, the two specimens could be collected simultaneously
170 and then tested in a staged reflex algorithm. By design, oral swabs are easy and inexpensive to
171 collect from any patient, in any setting. Swabs can therefore be collected and stored
172 concurrently with the collection of all urine samples. If a patient's urine sample is positive for
173 LAM, then that is diagnostic for TB and a swab test is not needed. If the urine LAM test is
174 negative, then the swab can be tested to avoid having to recall the patient for sputum induction.

175 In conclusion, our results indicate that tongue swabs and urine can serve as
176 complementary non-sputum samples for improved diagnosis of TB in PWH. With further
177 optimization to improve sensitivity, this approach may be considered as a fully non-sputum
178 strategy for detecting TB in sputum-scarce patients.

179
180

181

182

183 **Footnote page**

184 Conflict of interest statement: The authors have no conflicts of interest to declare.

185

186 This work was supported by the Bill and Melinda Gates Foundation (#INV-004527, OPP

187 1213054), by NIH grants R01AI139254 and U54EB027049. REDCap at ITHS is supported by

188 the National Center For Advancing Translational Sciences of the National Institutes of Health

189 under Award Number UL1 TR002319. AES is supported by NIH (NIAID) K23A140918. We are

190 grateful to Cepheid, Inc., for providing research-use-only Xpert Ultra test kits, and to Copan

191 Italia for providing swabs.

192

193 This work was presented in part at virtual TB Science 2021, (Abstract #TBS-LB-2021-02134)

194


195

196

197
198
199
200
201
202
203

Figure 1. Venn diagram showing overlap of the 2 non-sputum tests (tongue swab and urine LAM) and the sputum TB reference (Xpert Ultra or TB culture). The number of positive participants falling within each category is shown (N=131 participants).

*One TB ref+/OSA- participant had an invalid LAM result.



221
222
223
224
225
226
227

Table 1. Sensitivity and specificity of non-sputum tests alone or in combination, compared to TB reference standard (sputum Xpert Ultra or sputum culture).

	Sensitivity	Specificity
Tongue Swab (OSA) Cq<32	25/64 (39%)	65/67 (97%)
Tongue Swab (OSA) Cq<38	42/64 (67%)	52/67 (78%)
Urine LF-LAM	22/63 (35%)	67/67 (100%)
LAM or OSA* _{Cq<32}	36/63 (57%)	65/67 (97%)
LAM or OSA* _{Cq<38}	45/63 (71%)	52/67 (78%)

228 * OSA by manual qPCR using 2 thresholds of positivity: Cq<38 (liberal) and Cq<32 (stringent).
229

230 **Literature cited**

- 231
- 232
- 233 1. World Health Organization. Global Tuberculosis Report 2020.
- 234 2. UNITAID. Tuberculosis diagnostics technology and market landscape - 5th edition.
- 235 World Health Organization. 2017.
- 236 3. Fauci, AS, Eisinger RW. Reimagining the Research Approach to Tuberculosis. *Am J*
- 237 *Trop Med Hyg.* 2018;98(3):650-2.
- 238 4. Shah M, Hanrahan C, Wang ZY, Dendukuri N, Lawn SD, Denkinger CM, et al. Lateral
- 239 flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults.
- 240 *Cochrane Database of Systematic Reviews.* 2016;(5).
- 241 5. Broger T, Sossen B, du Toit E, Kerkhoff AD, Schutz C, Ivanova Reipold E, et al. Novel
- 242 lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy
- 243 study. *The Lancet Infectious Diseases.* 2019;19(8):852-61.
- 244 6. LaCourse SM, Seko E, Wood R, Bundi W, Ouma GS, Agaya J, et al. Diagnostic
- 245 performance of oral swabs for non-sputum based TB diagnosis in a TB/HIV endemic setting.
- 246 *PLoS One.* 2022;17(1):e0262123. Epub 2022/01/14.
- 247 7. Wood RC, Andama A, Hermansky G, Burkot S, Asege L, Job M, et al. Characterization
- 248 of oral swab samples for diagnosis of pulmonary tuberculosis. *PLOS ONE.*
- 249 2021;16(5):e0251422. doi: 10.1371/journal.pone.0251422.
- 250 8. Luabeya AK, Wood RC, Shenje J, Filander E, Ontong C, Mabwe S, et al. Noninvasive
- 251 Detection of Tuberculosis by Oral Swab Analysis. *Journal of Clinical Microbiology.*
- 252 2019;57(3):e01847-18.
- 253 9. Wood RC, Luabeya AK, Weigel KM, Wilbur AK, Jones-Engel L, Hatherill M, et al.
- 254 Detection of Mycobacterium tuberculosis DNA on the oral mucosa of tuberculosis patients.
- 255 *Scientific Reports.* 2015;5:8668.
- 256 10. Nicol MP, Wood RC, Workman L, Prins M, Whitman C, Ghebrekristos Y, et al.
- 257 Microbiological diagnosis of pulmonary tuberculosis in children by oral swab polymerase chain
- 258 reaction. *Scientific Reports.* 2019;9(1):10789.
- 259 11. Valinetz ED, Cangelosi GA. A Look Inside: Oral Sampling for Detection of Non-Oral
- 260 Infectious Diseases. *Journal of Clinical Microbiology.* 2021;JCM.02360-20.
- 261 12. Flores JA, Calderon R, Mesman AW, Soto M, Coit J, Aliaga J, et al. Detection of
- 262 Mycobacterium Tuberculosis DNA in Buccal Swab Samples from Children in Lima, Peru. *The*
- 263 *Pediatric Infectious Disease Journal.* 2020;39(11).
- 264 13. Mesman AW, Calderon R, Soto M, Coit J, Aliaga J, Mendoza M, et al. Mycobacterium
- 265 tuberculosis detection from oral swabs with Xpert MTB/RIF ULTRA: a pilot study. *BMC Res*
- 266 *Notes.* 2019;12(1):349-.
- 267 14. Song Y, Ma Y, Liu R, Shang Y, Ma L, Huo F, et al. Diagnostic Yield of Oral Swab
- 268 Testing by TB-LAMP for Diagnosis of Pulmonary Tuberculosis. *Infect Drug Resist.* 2021;14:89-
- 269 95.
- 270